Roles of O-GlcNAc in chronic diseases of aging

Molecular Aspects of Medicine

Volumn 51, Issue , 2016, Pages 1-15

  Banerjee, Partha S ^a   Lagerlöf, Olof ^a   Hart, Gerald W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes; Hexosamine biosynthetic pathway; Hyperglycemia; Neurodegenerative disease; O GlcNAc; O GlcNAc transferase; O GlcNAcase

Indexed keywords

N ACETYLGLUCOSAMINE; O LINKED N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG; N ACETYLGLUCOSAMINYLTRANSFERASE; O-GLCNAC TRANSFERASE;

AGING; ALZHEIMER DISEASE; BREAST CANCER; CARDIOMYOPATHY; CELL DIVISION; CELL GROWTH; CELL METABOLISM; CHRONIC DISEASE; COLON CANCER; CYTOKINE PRODUCTION; DEMENTIA; DIABETES MELLITUS; HUMAN; KIDNEY DISEASE; LARYNX CANCER; LIVER CANCER; LUNG CANCER; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; DEGENERATIVE DISEASE; HEART DISEASE; HYPERGLYCEMIA; INFLAMMATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLGLUCOSAMINE; AGING; CHRONIC DISEASE; DIABETES MELLITUS; HEART DISEASES; HUMANS; HYPERGLYCEMIA; INFLAMMATION; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84973161413     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2016.05.005     Document Type: Review

References (181)

1. Akimoto, Y., Kreppel, L.K., Hirano, H., Hart, G.W., Localization of the O-linked N-acetylglucosamine transferase in rat pancreas. Diabetes 48:12 (1999), 2407–2413.
2. Akimoto, Y., Kreppel, L.K., Hirano, H., Hart, G.W., Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia 43:10 (2000), 1239–1247.
3. Akimoto, Y., Comer, F.I., Cole, R.N., Kudo, A., Kawakami, H., Hirano, H., et al. Localization of the O-GlcNAc transferase and O-GlcNAc-modified proteins in rat cerebellar cortex. Brain Res 966:2 (2003), 194–205.
4. Akimoto, Y., Kawakami, H., Yamamoto, K., Munetomo, E., Hida, T., Hirano, H., Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats. Invest. Ophthalmol. Vis. Sci 44:9 (2003), 3802–3809.
5. Akimoto, Y., Hart, G.W., Wells, L., Vosseller, K., Yamamoto, K., Munetomo, E., et al. Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats. Glycobiology 17:2 (2007), 127–140.
6. Andrali, S.S., Qian, Q., Ozcan, S., Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J. Biol. Chem 282:21 (2007), 15589–15596.
7. Arias, E.B., Kim, J., Cartee, G.D., Prolonged incubation in PUGNAc results in increased protein O-linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes 53:4 (2004), 921–930.
8. Arnold, C.S., Johnson, G.V., Cole, R.N., Dong, D.L., Lee, M., Hart, G.W., The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem 271:46 (1996), 28741–28744.
9. Balkhi, M.Y., Trivedi, A.K., Geletu, M., Christopeit, M., Bohlander, S.K., Behre, H.M., et al. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 25:53 (2006), 7041–7058.
10. Ball, L.E., Berkaw, M.N., Buse, M.G., Identification of the major site of O-linked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. Mol. Cell. Proteomics 5:2 (2006), 313–323.
11. Banerjee, P.S., Hart, G.W., Cho, J.W., Chemical approaches to study O-GlcNAcylation. Chem. Soc. Rev 42:10 (2013), 4345–4357.
12. Banerjee, P.S., Ma, J., Hart, G.W., Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc. Natl. Acad. Sci. U.S.A. 112:19 (2015), 6050–6055.
13. Banerjee, S., Sangwan, V., McGinn, O., Chugh, R., Dudeja, V., Vickers, S.M., et al. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J. Biol. Chem 288:47 (2013), 33927–33938.
14. Bennett, C.E., Johnsen, V.L., Shearer, J., Belke, D.D., Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci 92:11 (2013), 657–663.
15. Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:5500 (2000), 2302–2303.
16. Bobsin, K., Kreienkamp, H.J., Severe learning deficits of IRSp53 mutant mice are caused by altered NMDA receptor dependent signal transduction. J. Neurochem, 2015, 10.1111/jnc.13428.
17. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest 122:4 (2012), 1339–1353.
18. Bond, M.R., Hanover, J.A., A little sugar goes a long way: the cell biology of O-GlcNAc. J. Cell Biol 208:7 (2015), 869–880.
19. Borghgraef, P., Menuet, C., Theunis, C., Louis, J.V., Devijver, H., Maurin, H., et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS ONE, 8(12), 2013 e84442.
20. Brister, M.A., Pandey, A.K., Bielska, A.A., Zondlo, N.J., OGlcNAcylation and phosphorylation have opposing structural effects in tau: phosphothreonine induces particular conformational order. J. Am. Chem. Soc 136:10 (2014), 3803–3816.
21. Bruce, D.G., Type 2 diabetes and cognitive function: many questions, few answers. Lancet Neurol 14:3 (2015), 241–242.
22. Buse, M.G., Robinson, K.A., Marshall, B.A., Hresko, R.C., Mueckler, M.M., Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles. Am. J. Physiol. Endocrinol. Metab 283:2 (2002), E241–E250.
23. Butkinaree, C., Park, K., Hart, G.W., O-linked [beta]-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta 1800:2 (2010), 96–106.
24. Caldwell, S.A., Jackson, S.R., Shahriari, K.S., Lynch, T.P., Sethi, G., Walker, S., et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 29:19 (2010), 2831–2842.
25. Cha, M.Y., Cho, H.J., Kim, C., Jung, Y.O., Kang, M.J., Murray, M.E., et al. Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. Hum. Mol. Genet 24:22 (2015), 6492–6504.
26. Chaiyawat, P., Chokchaichamnankit, D., Lirdprapamongkol, K., Srisomsap, C., Svasti, J., Champattanachai, V., Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells. Oncol. Rep 34:4 (2015), 1933–1942.
27. Champattanachai, V., Marchase, R.B., Chatham, J.C., Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am. J. Physiol. Cell Physiol 292:1 (2007), C178–C187.
28. Champattanachai, V., Netsirisawan, P., Chaiyawat, P., Phueaouan, T., Charoenwattanasatien, R., Chokchaichamnankit, D., et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics 13:14 (2013), 2088–2099.
29. Chen, P.Y., Lin, C.C., Chang, Y.T., Lin, S.C., Chan, S.I., One O-linked sugar can affect the coil-to-beta structural transition of the prion peptide. Proc. Natl. Acad. Sci. U.S.A. 99:20 (2002), 12633–12638.
30. Chen, Y.X., Du, J.T., Zhou, L.X., Liu, X.H., Zhao, Y.F., Nakanishi, H., et al. Alternative O-GlcNAcylation/O-phosphorylation of Ser16 induce different conformational disturbances to the N terminus of murine estrogen receptor beta. Chem. Biol 13:9 (2006), 937–944.
31. Cheung, W.D., Hart, G.W., AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem 283:19 (2008), 13009–13020.
32. Chou, T.-Y., Hart, G.W., Dang, C.V., c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem 270:32 (1995), 18961–18965.
33. Cieniewski-Bernard, C., Bastide, B., Lefebvre, T., Lemoine, J., Mounier, Y., Michalski, J.C., Identification of O-linked N-acetylglucosamine proteins in rat skeletal muscle using two-dimensional gel electrophoresis and mass spectrometry. Mol. Cell. Proteomics 3:6 (2004), 577–585.
34. Cieniewski-Bernard, C., Mounier, Y., Michalski, J.C., Bastide, B., O-GlcNAc level variations are associated with the development of skeletal muscle atrophy. J. Appl. Physiol 100:5 (2006), 1499–1505.
35. Clark, R.J., McDonough, P.M., Swanson, E., Trost, S.U., Suzuki, M., Fukuda, M., et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem 278:45 (2003), 44230–44237.
36. Cole, R.N., Hart, G.W., Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem 79:5 (2001), 1080–1089.
37. Cooper, C., Sommerlad, A., Lyketsos, C.G., Livingston, G., Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am. J. Psychiatry 172:4 (2015), 323–334.
38. Dassanayaka, S., Jones, S.P., O-GlcNAc and the cardiovascular system. Pharmacol. Ther 142:1 (2014), 62–71.
39. Dauphinee, S.M., Ma, M., Too, C.K.L., Role of O-linked β-N-acetylglucosamine modification in the subcellular distribution of alpha4 phosphoprotein and Sp1 in rat lymphoma cells. J. Cell. Biochem 96:3 (2005), 579–588.
40. De Felice, F.G., Vieira, M.N., Bomfim, T.R., Decker, H., Velasco, P.T., Lambert, M.P., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc. Natl. Acad. Sci. U.S.A. 106:6 (2009), 1971–1976.
41. Degrell, P., Cseh, J., Mohas, M., Molnar, G.A., Pajor, L., Chatham, J.C., et al. Evidence of O-linked N-acetylglucosamine in diabetic nephropathy. Life Sci 84:13–14 (2009), 389–393.
42. Deng, Y., Li, B., Liu, F., Iqbal, K., Grundke-Iqbal, I., Brandt, R., et al. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J. 22:1 (2008), 138–145.
43. Dentin, R., Hedrick, S., Xie, J., Yates, J. 3rd, Montminy, M., Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319:5868 (2008), 1402–1405.
44. Dias, W.B., Hart, G.W., O-GlcNAc modification in diabetes and Alzheimer's disease. Mol. Biosyst 3:11 (2007), 766–772.
45. Durning, S.P., Flanagan-Steet, H., Prasad, N., Wells, L., O-linked beta-N-acetylglucosamine (O-GlcNAc) acts as a glucose sensor to epigenetically regulate the insulin gene in pancreatic beta cells. J. Biol. Chem 291:5 (2016), 2107–2118.
46. Escribano, L., Simon, A.M., Gimeno, E., Cuadrado-Tejedor, M., Lopez de Maturana, R., Garcia-Osta, A., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35:7 (2010), 1593–1604.
47. Facundo, H.T., Brainard, R.E., Watson, L.J., Ngoh, G.A., Hamid, T., Prabhu, S.D., et al. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am. J. Physiol. Heart Circ. Physiol 302:10 (2012), H2122–H2130.
48. Ferrer, C.M., Lynch, T.P., Sodi, V.L., Falcone, J.N., Schwab, L.P., Peacock, D.L., et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol. Cell 54:5 (2014), 820–831.
49. Forster, S., Welleford, A.S., Triplett, J.C., Sultana, R., Schmitz, B., Butterfield, D.A., Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim. Biophys. Acta 1842:9 (2014), 1333–1339.
50. Gao, Y., Wells, L., Comer, F.I., Parker, G.J., Hart, G.W., Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem 276:13 (2001), 9838–9845.
51. Gao, Y., Miyazaki, J., Hart, G.W., The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. Arch. Biochem. Biophys 415:2 (2003), 155–163.
52. Garvey, W.T., Olefsky, J.M., Matthaei, S., Marshall, S., Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes. A new mechanism of insulin resistance. J. Biol. Chem 262:1 (1987), 189–197.
53. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res 107:9 (2010), 1058–1070.
54. Golks, A., Guerini, D., The O-linked N-acetylglucosamine modification in cellular signalling and the immune system. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep 9:8 (2008), 748–753.
55. Golks, A., Tran, T.T., Goetschy, J.F., Guerini, D., Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes activation. EMBO J. 26:20 (2007), 4368–4379.
56. Graham, D.L., Gray, A.J., Joyce, J.A., Yu, D., O'Moore, J., Carlson, G.A., et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology 79 (2014), 307–313.
57. Griffith, L.S., Schmitz, B., O-linked N-acetylglucosamine is upregulated in Alzheimer brains. Biochem. Biophys. Res. Commun 213:2 (1995), 424–431.
58. Griffith, L.S., Mathes, M., Schmitz, B., Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine. J. Neurosci. Res 41:2 (1995), 270–278.
59. Grillo, C.A., Piroli, G.G., Lawrence, R.C., Wrighten, S.A., Green, A.J., Wilson, S.P., et al. Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 64:11 (2015), 3927–3936.
60. Gudala, K., Bansal, D., Schifano, F., Bhansali, A., Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J. Diabetes Investig 4:6 (2013), 640–650.
61. Guinez, C., Mir, A.-M., Dehennaut, V., Cacan, R., Harduin-Lepers, A., Michalski, J.-C., et al. Protein ubiquitination is modulated by O-GlcNAc glycosylation. FASEB J. 22:8 (2008), 2901–2911.
62. Guinez, C., Filhoulaud, G., Rayah-Benhamed, F., Marmier, S., Dubuquoy, C., Dentin, R., et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 60:5 (2011), 1399–1413.
63. Gurel, Z., Sieg, K.M., Shallow, K.D., Sorenson, C.M., Sheibani, N., Retinal O-linked N-acetylglucosamine protein modifications: implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol. Vis 19 (2013), 1047–1059.
64. Gurel, Z., Zaro, B.W., Pratt, M.R., Sheibani, N., Identification of O-GlcNAc modification targets in mouse retinal pericytes: implication of p53 in pathogenesis of diabetic retinopathy. PLoS ONE, 9(5), 2014 e95561.
65. Hanover, J.A., Lai, Z., Lee, G., Lubas, W.A., Sato, S.M., Elevated O-linked N-acetylglucosamine metabolism in pancreatic beta-cells. Arch. Biochem. Biophys 362:1 (1999), 38–45.
66. Hart, G.W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem 80:1 (2011), 825–858.
67. Hart, G.W., Slawson, C., Ramirez-Correa, G., Lagerlof, O., Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem 80 (2011), 825–858.
68. Hascall, V.C., Wang, A., Tammi, M., Oikari, S., Tammi, R., Passi, A., et al. The dynamic metabolism of hyaluronan regulates the cytosolic concentration of UDP-GlcNAc. Matrix Biol 35 (2014), 14–17.
69. Heckel, D., Comtesse, N., Brass, N., Blin, N., Zang, K.D., Meese, E., Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum. Mol. Genet 7:12 (1998), 1859–1872.
70. Hedou, J., Cieniewski-Bernard, C., Leroy, Y., Michalski, J.C., Mounier, Y., Bastide, B., O-linked N-acetylglucosaminylation is involved in the Ca2+ activation properties of rat skeletal muscle. J. Biol. Chem 282:14 (2007), 10360–10369.
71. Heilig, C.W., Concepcion, L.A., Riser, B.L., Freytag, S.O., Zhu, M., Cortes, P., Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J. Clin. Invest 96:4 (1995), 1802–1814.
72. Holt, G.D., Hart, G.W., The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J. Biol. Chem 261:17 (1986), 8049–8057.
73. Housley, M.P., Rodgers, J.T., Udeshi, N.D., Kelly, T.J., Shabanowitz, J., Hunt, D.F., et al. O-GlcNAc regulates FoxO activation in response to glucose. J. Biol. Chem 283:24 (2008), 16283–16292.
74. Housley, M.P., Udeshi, N.D., Rodgers, J.T., Shabanowitz, J., Puigserver, P., Hunt, D.F., et al. A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose. J. Biol. Chem 284:8 (2009), 5148–5157.
75. Hu, Y., Belke, D., Suarez, J., Swanson, E., Clark, R., Hoshijima, M., et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ. Res 96:9 (2005), 1006–1013.
76. Hu, Y., Suarez, J., Fricovsky, E., Wang, H., Scott, B.T., Trauger, S.A., et al. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J. Biol. Chem 284:1 (2009), 547–555.
77. Huang, X., Pan, Q., Sun, D., Chen, W., Shen, A., Huang, M., et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J. Biol. Chem 288:51 (2013), 36418–36425.
78. Hwang, S.Y., Shin, J.H., Hwang, J.S., Kim, S.Y., Shin, J.A., Oh, E.S., et al. Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury. Glia 58:15 (2010), 1881–1892.
79. Hwang, S.Y., Hwang, J.S., Kim, S.Y., Han, I.O., O-GlcNAcylation and p50/p105 binding of c-Rel are dynamically regulated by LPS and glucosamine in BV2 microglia cells. Br. J. Pharmacol 169:7 (2013), 1551–1560.
80. Ishii, K., PET approaches for diagnosis of dementia. AJNR Am. J. Neuroradiol 35:11 (2014), 2030–2038.
81. Itkonen, H.M., Minner, S., Guldvik, I.J., Sandmann, M.J., Tsourlakis, M.C., Berge, V., et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res 73:16 (2013), 5277–5287.
82. Jacobsen, K.T., Iverfeldt, K., O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP). Biochem. Biophys. Res. Commun 404:3 (2011), 882–886.
83. James, L.R., Tang, D., Ingram, A., Ly, H., Thai, K., Cai, L., et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes 51:4 (2002), 1146–1156.
84. Jensen, R.V., Zachara, N.E., Nielsen, P.H., Kimose, H.H., Kristiansen, S.B., Botker, H.E., Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc. Res 97:2 (2013), 369–378.
85. Johnsen, V.L., Belke, D.D., Hughey, C.C., Hittel, D.S., Hepple, R.T., Koch, L.G., et al. Enhanced cardiac protein glycosylation (O-GlcNAc) of selected mitochondrial proteins in rats artificially selected for low running capacity. Physiol. Genomics 45:1 (2013), 17–25.
86. Jones, S.P., Zachara, N.E., Ngoh, G.A., Hill, B.G., Teshima, Y., Bhatnagar, A., et al. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation 117:9 (2008), 1172–1182.
87. Kearse, K.P., Hart, G.W., Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 88:5 (1991), 1701–1705.
88. Kim, C., Nam, D.W., Park, S.Y., Song, H., Hong, H.S., Boo, J.H., et al. O-linked beta-N-acetylglucosaminidase inhibitor attenuates beta-amyloid plaque and rescues memory impairment. Neurobiol. Aging 34:1 (2013), 275–285.
89. Kneass, Z.T., Marchase, R.B., Neutrophils exhibit rapid agonist-induced increases in protein-associated O-GlcNAc. J. Biol. Chem 279:44 (2004), 45759–45765.
90. Kneass, Z.T., Marchase, R.B., Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils. J. Biol. Chem 280:15 (2005), 14579–14585.
91. Kreppel, L.K., Blomberg, M.A., Hart, G.W., Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem 272:14 (1997), 9308–9315.
92. Krzeslak, A., Pomorski, L., Lipinska, A., Elevation of nucleocytoplasmic β-N-acetylglucosaminidase (O-GlcNAcase) activity in thyroid cancers. Int. J. Mol. Med 25:4 (2010), 643–648.
93. Lagerlof, O., Hart, G.W., O-GlcNAcylation of neuronal proteins: roles in neuronal functions and in neurodegeneration. Adv. Neurobiol 9 (2014), 343–366.
94. Lagerlof, O., Slocomb, J.E., Hong, I., Aponte, Y., Blackshaw, S., Hart, G.W., et al. The nutrient sensor OGT in PVN neurons regulates feeding. Science 351:6279 (2016), 1293–1296.
95. Lefebvre, T., Pinte, S., Guérardel, C., Deltour, S., Martin-Soudant, N., Slomianny, M.-C., et al. The tumor suppressor HIC1 (hypermethylated in cancer 1) is O-GlcNAc glycosylated. Eur. J. Biochem 271:19 (2004), 3843–3854.
96. Lehman, D.M., Fu, D.J., Freeman, A.B., Hunt, K.J., Leach, R.J., Johnson-Pais, T., et al. A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican Americans. Diabetes 54:4 (2005), 1214–1221.
97. Li, X., Lu, F., Wang, J.Z., Gong, C.X., Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur. J. Neurosci 23:8 (2006), 2078–2086.
98. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G.W., Gong, C.X., O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101:29 (2004), 10804–10809.
99. Liu, J., Pang, Y., Chang, T., Bounelis, P., Chatham, J.C., Marchase, R.B., Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J. Mol. Cell. Cardiol 40:2 (2006), 303–312.
100. Liu, Y., Li, X., Yu, Y., Shi, J., Liang, Z., Run, X., et al. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain. PLoS ONE, 7(8), 2012 e43724.
101. Ludemann, N., Clement, A., Hans, V.H., Leschik, J., Behl, C., Brandt, R., O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). J. Biol. Chem 280:36 (2005), 31648–31658.
102. Lynch, T.P., Ferrer, C.M., Jackson, S.R., Shahriari, K.S., Vosseller, K., Reginato, M.J., Critical role of O-Linked β-N-Acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem 287:14 (2012), 11070–11081.
103. Ma, J., Liu, T., Wei, A.C., Banerjee, P., O'Rourke, B., Hart, G.W., O-GlcNAcomic profiling identifies widespread O-linked beta-N-acetylglucosamine modification (O-GlcNAcylation) in oxidative phosphorylation system regulating cardiac mitochondrial function. J. Biol. Chem 290:49 (2015), 29141–29153.
104. Ma, Z., Vocadlo, D.J., Vosseller, K., Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J. Biol. Chem 288:21 (2013), 15121–15130.
105. Macauley, M.S., Shan, X., Yuzwa, S.A., Gloster, T.M., Vocadlo, D.J., Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem. Biol 17:9 (2010), 949–958.
106. Marotta, N.P., Cherwien, C.A., Abeywardana, T., Pratt, M.R., O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation. Chembiochem 13:18 (2012), 2665–2670.
107. Marotta, N.P., Lin, Y.H., Lewis, Y.E., Ambroso, M.R., Zaro, B.W., Roth, M.T., et al. O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease. Nat. Chem 7:11 (2015), 913–920.
108. Marsh, S.A., Powell, P.C., Dell'italia, L.J., Chatham, J.C., Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci 92:11 (2013), 648–656.
109. Marsh, S.A., Collins, H.E., Chatham, J.C., Protein O-GlcNAcylation and cardiovascular (patho)physiology. J. Biol. Chem 289:50 (2014), 34449–34456.
110. Marshall, S., Bacote, V., Traxinger, R.R., Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem 266:8 (1991), 4706–4712.
111. Marz, P., Stetefeld, J., Bendfeldt, K., Nitsch, C., Reinstein, J., Shoeman, R.L., et al. Ataxin-10 interacts with O-linked beta-N-acetylglucosamine transferase in the brain. J. Biol. Chem 281:29 (2006), 20263–20270.
112. Mazars, R., Gonzalez-de-Peredo, A., Cayrol, C., Lavigne, A.C., Vogel, J.L., Ortega, N., et al. The THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias. J. Biol. Chem 285:18 (2010), 13364–13371.
113. McClain, D.A., Lubas, W.A., Cooksey, R.C., Hazel, M., Parker, G.J., Love, D.C., et al. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc. Natl. Acad. Sci. U.S.A. 99:16 (2002), 10695–10699.
114. Mi, W., Gu, Y., Han, C., Liu, H., Fan, Q., Zhang, X., et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim. Biophys. Acta 1812:4 (2011), 514–519.
115. Moreira, P.I., Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J. Alzheimers Dis 30:Suppl. 2 (2012), S199–S215.
116. Mosconi, L., Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32:4 (2005), 486–510.
117. Muller, U., Steinberger, D., Nemeth, A.H., Clinical and molecular genetics of primary dystonias. Neurogenetics 1:3 (1998), 165–177.
118. Nagel, A.K., Ball, L.E., Intracellular protein O-GlcNAc modification integrates nutrient status with transcriptional and metabolic regulation. Adv. Cancer Res 126 (2015), 137–166.
119. Nagy, T., Champattanachai, V., Marchase, R.B., Chatham, J.C., Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine. Am. J. Physiol. Cell Physiol 290:1 (2006), C57–C65.
120. Ngoh, G.A., Watson, L.J., Facundo, H.T., Dillmann, W., Jones, S.P., Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J. Mol. Cell. Cardiol 45:2 (2008), 313–325.
121. Ngoh, G.A., Hamid, T., Prabhu, S.D., Jones, S.P., O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am. J. Physiol. Heart Circ. Physiol 297:5 (2009), H1711–H1719.
122. Ngoh, G.A., Watson, L.J., Facundo, H.T., Jones, S.P., Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids 40:3 (2011), 895–911.
123. Nolte, D., Muller, U., Human O-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. Mamm. Genome 13:1 (2002), 62–64.
124. O'Donnell, N., Zachara, N.E., Hart, G.W., Marth, J.D., Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol. Cell. Biol 24:4 (2004), 1680–1690.
125. Park, K., Saudek, C.D., Hart, G.W., Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes. Diabetes 59:7 (2010), 1845–1850.
126. Parker, G., Taylor, R., Jones, D., McClain, D., Hyperglycemia and inhibition of glycogen synthase in streptozotocin-treated mice: role of O-linked N-acetylglucosamine. J. Biol. Chem 279:20 (2004), 20636–20642.
127. Pekkurnaz, G., Trinidad, J.C., Wang, X., Kong, D., Schwarz, T.L., Glucose regulates mitochondrial motility via Milton modification by O-GlcNAc transferase. Cell 158:1 (2014), 54–68.
128. Peterson, S.B., Hart, G.W., New insights: a role for O-GlcNAcylation in diabetic complications. Crit. Rev. Biochem. Mol. Biol 51:3 (2016), 150–161 1–12.
129. Phoomak, C., Silsirivanit, A., Wongkham, C., Sripa, B., Puapairoj, A., Wongkham, S., Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac. J. Cancer Prev 13 (2012), 101–105 (KK).
130. Qizilbash, N., Gregson, J., Johnson, M.E., Pearce, N., Douglas, I., Wing, K., et al. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol 3:6 (2015), 431–436.
131. Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N. Engl. J. Med 362:4 (2010), 329–344.
132. Ramirez-Correa, G.A., Jin, W., Wang, Z., Zhong, X., Gao, W.D., Dias, W.B., et al. O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. Circ. Res 103:12 (2008), 1354–1358.
133. Ramirez-Correa, G.A., Ma, J., Slawson, C., Zeidan, Q., Lugo-Fagundo, N.S., Xu, M., et al. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ Sensitivity in diabetic cardiac muscle. Diabetes 64:10 (2015), 3573–3587.
134. Ranuncolo, S.M., Ghosh, S., Hanover, J.A., Hart, G.W., Lewis, B.A., Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo. J. Biol. Chem 287:28 (2012), 23549–23561.
135. Remuzzi, G., Macia, M., Ruggenenti, P., Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J. Am. Soc. Nephrol 17:4 Suppl. 2 (2006), S90–S97.
136. Robinson, K.A., Ball, L.E., Buse, M.G., Reduction of O-GlcNAc protein modification does not prevent insulin resistance in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab 292:3 (2007), E884–E890.
137. Ruan, H.B., Han, X., Li, M.D., Singh, J.P., Qian, K., Azarhoush, S., et al. O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1alpha stability. Cell Metab 16:2 (2012), 226–237.
138. Ruan, H.B., Dietrich, M.O., Liu, Z.W., Zimmer, M.R., Li, M.D., Singh, J.P., et al. O-GlcNAc transferase enables AgRP neurons to suppress browning of white fat. Cell 159:2 (2014), 306–317.
139. Shi, Y., Tomic, J., Wen, F., Shaha, S., Bahlo, A., Harrison, R., et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia 24:9 (2010), 1588–1598.
140. Slawson, C., Pidala, J., Potter, R., Increased N-acetyl-β-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim. Biophys. Acta 1537:2 (2001), 147–157.
141. Slawson, C., Zachara, N.E., Vosseller, K., Cheung, W.D., Lane, M.D., Hart, G.W., Perturbations in O-linked β-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J. Biol. Chem 280:38 (2005), 32944–32956.
142. Slawson, C., Copeland, R.J., Hart, G.W., O-GlcNAc signaling: a metabolic link between diabetes and cancer?. Trends Biochem. Sci 35:10 (2010), 547–555.
143. Smet-Nocca, C., Broncel, M., Wieruszeski, J.M., Tokarski, C., Hanoulle, X., Leroy, A., et al. Identification of O-GlcNAc sites within peptides of the tau protein and their impact on phosphorylation. Mol. Biosyst 7:5 (2011), 1420–1429.
144. Sodi, V.L., Khaku, S., Krutilina, R., Schwab, L.P., Vocadlo, D.J., Seagroves, T.N., et al. mTOR/MYC axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer. Mol. Cancer Res 13:5 (2015), 923–933.
145. Starska, K., Forma, E., Brzezińska-Błaszczyk, E., Lewy-Trenda, I., Bryś, M., Jóźwiak, P., et al. Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer. Clin. Exp. Med 15:4 (2015), 455–468.
146. Tan, E.P., Villar, M.T., E, L., Lu, J., Selfridge, J.E., Artigues, A., et al. Altering O-linked beta-N-acetylglucosamine cycling disrupts mitochondrial function. J. Biol. Chem 289:21 (2014), 14719–14730.
147. Taylor, E.W., Wang, K., Nelson, A.R., Bredemann, T.M., Fraser, K.B., Clinton, S.M., et al. O-GlcNAcylation of AMPA receptor GluA2 is associated with a novel form of long-term depression at hippocampal synapses. J. Neurosci 34:1 (2014), 10–21.
148. Torres, C.R., Hart, G.W., Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem 259:5 (1984), 3308–3317.
149. Townsend, M., Mehta, T., Selkoe, D.J., Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem 282:46 (2007), 33305–33312.
150. Trinidad, J.C., Barkan, D.T., Gulledge, B.F., Thalhammer, A., Sali, A., Schoepfer, R., et al. Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol. Cell. Proteomics 11:8 (2012), 215–229.
151. Twine, N.A., Janitz, K., Wilkins, M.R., Janitz, M., Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS ONE, 6(1), 2011 e16266.
152. Vosseller, K., Wells, L., Lane, M.D., Hart, G.W., Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 99:8 (2002), 5313–5318.
153. Walgren, J.L., Vincent, T.S., Schey, K.L., Buse, M.G., High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin. Am. J. Physiol. Endocrinol. Metab 284:2 (2003), E424–E434.
154. Wang, P., Lazarus, B.D., Forsythe, M.E., Love, D.C., Krause, M.W., Hanover, J.A., O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 109:43 (2012), 17669–17674.
155. Wang, Z., Park, K., Comer, F., Hsieh-Wilson, L.C., Saudek, C.D., Hart, G.W., Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes. Diabetes 58:2 (2009), 309–317.
156. Wang, Z., Udeshi, N.D., O'Malley, M., Shabanowitz, J., Hunt, D.F., Hart, G.W., Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 9:1 (2010), 153–160.
157. Whelan, S.A., Lane, M.D., Hart, G.W., Regulation of the O-linked beta-N-acetylglucosamine transferase by insulin signaling. J. Biol. Chem 283:31 (2008), 21411–21417.
158. Whelan, S.A., Dias, W.B., Thiruneelakantapillai, L., Lane, M.D., Hart, G.W., Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J. Biol. Chem 285:8 (2010), 5204–5211.
159. Xing, D., Gong, K., Feng, W., Nozell, S.E., Chen, Y.F., Chatham, J.C., et al. O-GlcNAc modification of NFkappaB p65 inhibits TNF-alpha-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS ONE, 6(8), 2011 e24021.
160. Yang, W.H., Kim, J.E., Nam, H.W., Ju, J.W., Kim, H.S., Kim, Y.S., et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol 8:10 (2006), 1074–1083.
161. Yang, W.H., Park, S.Y., Nam, H.W., Kim, D.H., Kang, J.G., Kang, E.S., et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc. Natl. Acad. Sci. U.S.A. 105:45 (2008), 17345–17350.
162. Yang, X., Ongusaha, P.P., Miles, P.D., Havstad, J.C., Zhang, F., So, W.V., et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451:7181 (2008), 964–969.
163. Yehezkel, G., Cohen, L., Kliger, A., Manor, E., Khalaila, I., O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-β-d-glucosaminidase silencing on cell phenotype and transcriptome. J. Biol. Chem 287:34 (2012), 28755–28769.
164. Yi, W., Clark, P.M., Mason, D.E., Keenan, M.C., Hill, C., Goddard, W.A., et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337:6097 (2012), 975–980.
165. Yki-Jarvinen, H., Virkamaki, A., Daniels, M.C., McClain, D., Gottschalk, W.K., Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. Metabolism 47:4 (1998), 449–455.
166. Yu, C.H., Si, T., Wu, W.H., Hu, J., Du, J.T., Zhao, Y.F., et al. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau. Biochem. Biophys. Res. Commun 375:1 (2008), 59–62.
167. Yuzwa, S.A., Macauley, M.S., Heinonen, J.E., Shan, X., Dennis, R.J., He, Y., et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol 4:8 (2008), 483–490.
168. Yuzwa, S.A., Shan, X., Macauley, M.S., Clark, T., Skorobogatko, Y., Vosseller, K., et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol 8:4 (2012), 393–399.
169. Yuzwa, S.A., Cheung, A.H., Okon, M., McIntosh, L.P., Vocadlo, D.J., O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol 426:8 (2014), 1736–1752.
170. Yuzwa, S.A., Shan, X., Jones, B.A., Zhao, G., Woodward, M.L., Li, X., et al. Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. Mol. Neurodegener, 9, 2014, 42.
171. Zachara, N.E., O'Donnell, N., Cheung, W.D., Mercer, J.J., Marth, J.D., Hart, G.W., Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J. Biol. Chem 279:29 (2004), 30133–30142.
172. Zachara, N.E., O'Donnell, N., Cheung, W.D., Mercer, J.J., Marth, J.D., Hart, G.W., Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response of mammalian cells. J. Biol. Chem 279:29 (2004), 30133–30142.
173. Zeidan, Q., Wang, Z., De Maio, A., Hart, G.W., O-GlcNAc cycling enzymes associate with the translational machinery and modify core ribosomal proteins. Mol. Biol. Cell 21:12 (2010), 1922–1936.
174. Zhang, F., Su, K., Yang, X., Bowe, D.B., Paterson, A.J., Kudlow, J.E., O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115:6 (2003), 715–725.
175. Zhang, N., Chen, X., Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro. Biotechnol. Appl. Biochem, 2015, 10.1002/bab.1441 n/a-n/a.
176. Zhang, X., Ma, L., Qi, J., Shan, H., Yu, W., Gu, Y., MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy. Mol. Cell. Biochem 410:1–2 (2015), 101–110.
177. Zhang, Z., Tan, E.P., VandenHull, N.J., Peterson, K.R., Slawson, C., O-GlcNAcase expression is sensitive to changes in O-GlcNAc homeostasis. Front. Endocrinol. (Lausanne), 5, 2014, 206.
178. Zhu, Q., Zhou, L., Yang, Z., Lai, M., Xie, H., Wu, L., et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med. Oncol 29:2 (2012), 985–993.
179. Zhu, Y., Shan, X., Yuzwa, S.A., Vocadlo, D.J., The emerging link between O-GlcNAc and Alzheimer disease. J. Biol. Chem 289:50 (2014), 34472–34481.
180. Zhu-Mauldin, X., Marsh, S.A., Zou, L., Marchase, R.B., Chatham, J.C., Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes. J. Biol. Chem 287:46 (2012), 39094–39106.
181. Zou, L., Yang, S., Hu, S., Chaudry, I.H., Marchase, R.B., Chatham, J.C., The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Shock 27:4 (2007), 402–408.